{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:14:21Z","timestamp":1770484461968,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.vaccine.2011.03.009","type":"journal-article","created":{"date-parts":[[2011,4,3]],"date-time":"2011-04-03T01:35:39Z","timestamp":1301794539000},"page":"4264-4273","source":"Crossref","is-referenced-by-count":62,"title":["An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix\u2122 hexa is immunogenic, with an acceptable safety profile in 12\u201323-month-old children"],"prefix":"10.1016","volume":"29","author":[{"given":"Markus","family":"Knuf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Pantazi-Chatzikonstantinou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Pfletschinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irmingard","family":"Tichmann-Schumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartwig","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lothar","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Fischbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrike","family":"Zinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidemarie","family":"Pankow-Culot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassiliki","family":"Papaevangelou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Van der Wielen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.03.009_bib0005","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Meningococcal disease","volume":"344","author":"Rosenstein","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0010","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1586\/erv.09.37","article-title":"Expanding prevention of invasive meningococcal disease","volume":"8","author":"Pelton","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1574-6976.2006.00060.x","article-title":"A surveillance network for meningococcal disease in Europe","volume":"31","author":"Trotter","year":"2007","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0020","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998\u20132007: implications for prevention of meningococcal disease","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0025","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0030","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1097\/01.inf.0000147642.85129.05","article-title":"Global epidemiology of meningococcal disease and vaccine efficacy","volume":"23","author":"Pollard","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0035","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","article-title":"Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story","volume":"20","author":"Miller","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0040","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1016\/j.vaccine.2005.03.045","article-title":"Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain","volume":"23","author":"Larrauri","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0045","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5694\/j.1326-5377.2007.tb00828.x","article-title":"Impact of meningococcal C conjugate vaccine use in Australia","volume":"186","author":"Booy","year":"2007","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0050","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10096-006-0155-6","article-title":"Invasive meningococcal disease in children in Greece: comparison of serogroup A disease with disease caused by other serogroups","volume":"25","author":"Tsolia","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0055","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1073\/pnas.94.1.271","article-title":"Capsule switching of Neisseria meningitidis","volume":"94","author":"Swartley","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0060","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3201\/eid0808.010422","article-title":"Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000","volume":"8","author":"Aguilera","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0065","unstructured":"Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. Wkly Epidemiol Rec 2002;77:331\u20139."},{"key":"10.1016\/j.vaccine.2011.03.009_bib0070","unstructured":"MENACTRA (meningococcal groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine). Product information. October 2007 Sanofi Pasteur. [Internet]. Available from https:\/\/www.vaccineshoppe.com\/image.cfm?pi=589-05&image_type=product_pdf [accessed 13 October 2010]."},{"key":"10.1016\/j.vaccine.2011.03.009_bib0075","unstructured":"MENVEO\u00ae Meningococcal Group A, C, W135 and Y conjugate Vaccine Summary of Product Characteristics. Novartis Vaccines. [Internet]. Available from: http:\/\/www.medicines.org.uk\/emc\/medicine\/22866\/SPC\/Menveo%20Group%20A,%20C,%20W135%20and%20Y%20conjugate%20vaccine [accessed 13 October 2010]."},{"key":"10.1016\/j.vaccine.2011.03.009_bib0080","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.vaccine.2009.10.064","article-title":"A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children","volume":"28","author":"Knuf","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0085","series-title":"27th annual meeting of the European Society for Paediatric Infectious Diseases","article-title":"Immunogenicity of one dose of an investigational meningococcal tetravalent tetanus-toxoid conjugate (ACWY-TT) vaccine in 1\u20132 year-olds","author":"Vesikari","year":"2009"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0090","series-title":"28th annual meeting of the European Society for Paediatric Infectious Diseases","article-title":"Immunogenicity and safety of the co-administration of the MenACWY-TT conjugate vaccine with MMRV in toddlers","author":"Vesikari","year":"2010"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0095","series-title":"28th annual meeting of the European Society for Paediatric Infectious Diseases","article-title":"The meningococcal tetravalent tetanus toxoid conjugate vaccine (MenACWY-TT) is immunogenic and has an acceptable safety profile in toddlers 12\u201323 month","author":"Vesikari","year":"2010"},{"issue":"March","key":"10.1016\/j.vaccine.2011.03.009_bib0100","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0105","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2014serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0110","unstructured":"Centers for Disease Control and Prevention. Inadvertent misadministration of meningococcal conjugate vaccine\u2014United States, June\u2013August 2005. MMWR Morb Mortal Wkly Rep 2006;55:1016\u20137."},{"key":"10.1016\/j.vaccine.2011.03.009_bib0115","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0092-1157(83)80038-9","article-title":"A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera","volume":"11","author":"Melville-Smith","year":"1983","journal-title":"J Biol Stand"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0120","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1128\/JCM.20.4.772-774.1984","article-title":"Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum","volume":"20","author":"Camargo","year":"1984","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/BF02097184","article-title":"Acellular pertussis vaccine in adults: adverse reactions and immune response","volume":"6","author":"Granstr\u00f6m","year":"1987","journal-title":"Eur J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0130","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-1759(87)90289-4","article-title":"Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA)","volume":"103","author":"Karpinski","year":"1987","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0135","series-title":"Vaccines","first-page":"299","article-title":"Vaccine","author":"Mast","year":"2004"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0140","unstructured":"World Health Organization. Standard procedure for determining immunity to poliovirus using the microneutralization test. WHO\/EPI\/Gen 93; 1993."},{"key":"10.1016\/j.vaccine.2011.03.009_bib0145","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/147.6.1100","article-title":"The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b","volume":"147","author":"K\u00e4yhty","year":"1983","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0150","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/infdis\/149.6.1034","article-title":"The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b","volume":"149","author":"Anderson","year":"1984","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0155","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vaccine.2008.08.075","article-title":"Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15\u201325 years","volume":"27","author":"Ostergaard","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0160","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0165","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0170","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10096-009-0848-8","article-title":"Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers","volume":"29","author":"Halperin","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0175","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1097\/00006454-200210000-00019","article-title":"Dose escalation, safety and immunogenicity study of a tetravalent meninogococcal polysaccharide diphtheria conjugate vaccine in toddlers","volume":"21","author":"Rennels","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0180","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/adc.2006.111500","article-title":"C,Y and W-135 polysaccharide-protein conjugate vaccines","volume":"92","author":"Pace","year":"2007","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0185","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1586\/erv.09.32","article-title":"Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV\/Hib hexavalent vaccine)","volume":"8","author":"Zepp","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0190","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/14760584.8.3.265","article-title":"Prevention of meningococcal serogroup C disease by NeisVac-C","volume":"8","author":"Borrow","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0195","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/CVI.00384-09","article-title":"Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine","volume":"17","author":"Borrow","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0200","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/INF.0b013e3181b9a831","article-title":"A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months","volume":"29","author":"D\u00edez-Domingo","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0205","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/infdis\/135.1.94","article-title":"Cross-antigenicity and immunogenicity between capsular polysaccharides of group C Neisseria meningitidis and of Escherichia coli K92","volume":"135","author":"Glode","year":"1977","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0210","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1084\/jem.162.6.1837","article-title":"Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies","volume":"162","author":"Guirguis","year":"1985","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2011.03.009_bib0215","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1574-695X.2002.tb00597.x","article-title":"Analysis of Neisseria lactamica antigens putatively implicated in acquisition of natural immunity to Neisseria meningitidis","volume":"34","author":"Troncoso","year":"2002","journal-title":"FEMS Immunol Med Microbiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11003616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11003616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,21]],"date-time":"2021-11-21T01:45:25Z","timestamp":1637459125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11003616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":43,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0264410X11003616"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.03.009","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}